BioRestorative Therapies, Inc. · NASDAQ:BRTX

BioRestorative Therapies — Investor Presentation (June 2021)

22 slides from BioRestorative Therapies's investor presentation, June 2021

  1. Slide 1: BioRestorative Therapies

    EZ ——> bic eclorcie therapies

  2. Slide 2: Forward Looking Statement

    FORWARD LOOKING STATEMENT STATEMENTS IN THIS PRESENTATION, INCLUDING THE INFORMATION SET FORTH AS TO THE FUTURE FINANCIAL OR OPERATING PERFORMANCE OF BIORESTORATIVE THERAPIES, INC. (THE “COMPANY”) THAT ARE NOT CURRENT OR HISTORICAL FACTUAL STATEMENTS MAY CONSTITUTE “FORWARD LOOKING” INFORMATION WITH

  3. Slide 3: Leadership

    LEADERSHIP Chairman and CEO Vice President of R&D Lance Alstodt joined BioRestorative Therapies as its Chairman and Chief Executive Francisco Silva joined BRT in April 2011 and is Vice President of Research and Officer in November 2020. Mr. Alstodt brings over 25 years of experience in Development.

  4. Slide 4: Company Highlights

    COMPANY HIGHLIGHTS Disruptive Platform Technology in Cellular Therapy Addressing Multi-Billion Dollar Markets with Unmet Needs Diverse Pipeline Opportunities Strong Preliminary Data Indicative of Positive Trial Outcomes Multiple Clinical & Regulatory Accomplishments Strong Intellectual Property Prot

  5. Slide 5: Research & Development

    RESEARCH & DEVELOPMENT Hypoxic BM-MSC IC LUMBAR DISC DISEASE iii BADSC THERMOSTEM® TYPE 2 DIABETES @ cersiry qu» — “SS 5

  6. Slide 6: Key Cell-Based Therapy Programs

    KEY CELL-BASED THERAPY PROGRAMS • Lead investigational therapeutic product DISC/SPINE • Autologous (patient’s own) cell-based biologic • Hypoxic (low oxygen) cultured, bone marrow-derived BRTX-100 • Single intradiscal injection – anticipated 30 minute in-office procedure • Prior human data provides

  7. Slide 7: BRTX-100

    BRTX-100 Link to youtube video of BRTX-100 7

  8. Slide 8: Market Opportunity - BRTX-100

    MARKET OPPORTUNITY - BRTX 100 1 1 1 1 1. Trinity Partners Report, “Degenerative Disc Disease US Market Assessment (Phase I),” Feb. 2016, Slide 9 of report. 8

  9. Slide 9: Standard of Care: Clinical and Economic Problem

    STANDARD OF CARE: CLINICAL AND ECONOMIC PROBLEM CONSERVATIVE TREATMENTS SURGICAL TREATMENTS WITH RE-OP RATES OFTEN 10-20% THE BRTX-100 OFTEN RECURRENT ORAL MEDICATION TREATMENT SPINAL FUSION SURGERY DIFFERENCE $1,000 - $2,000 1, 4 $110,000 1, 5 Annually A single treatment using BRTX-100 is justifiab

  10. Slide 10: BRTX-100: Autologous Bone-Marrow Derived Biologic

    BRTX-100: AUTOLOGUS BONE-MARROW DERIVED BIOLOGIC Collection and Shipment of Patient’s Bone Marrow and Blood to Cell Production Manufacturer Thawing and Injection of Production of BRTX-100 BRTX-100 into Patient’s Disc Hypoxic Culturing of Stem Cells Shipment of BRTX-100 Formulation and Cryopreservati

  11. Slide 11: Positive Human Data

    POSITIVE HUMAN DATA HUMAN DATA FROM STUDIES OF THERAPIES SIMILAR TO BRTX-100 SHOW REDUCED PAIN, INCREASED FUNCTION, AND AN ABSENCE OF SIGNIFICANT SAFETY ISSUES WITH A DURABLE RESPONSE Journal of Translational Medicine Treatment of lumbar degenerative disc disease-associated radicular pain with cultu

  12. Slide 12: Defined Health Report

    DEFINED HEALTH REPORT In May 2018, Defined Health (a bio-consulting company) conducted a company sponsored blinded study with relevant key opinion leaders to provide an independent review of BRTX-100 Key Findings Include: • Stem-cell therapies have “great potential” to treat cLDD (and related therap

  13. Slide 13: Trial Design

    TRIAL DESIGN FDA Cleared IND 17275: Phase 2 Randomized, Controlled Study Design in Patients with cLDD Study Design and Patient Population e Study includes 99 subjects (2:1 product to placebo) @ 40 ,000,000 cells/dose e Included subjects will have only one symptomatic diseased disc e Primary efficacy

  14. Slide 14: Competitive Landscape

    COMPETITIVE LANDSCAPE BRTX-100 BRTX-100 adult stem cell biologic, MPC-06-ID: adult stem cell biologic, ADVANTAGES PRODUCT administered via 30-minute • Autologous cells means low to no risk of administered via anticipated & DESCRIPTION 30-minute in-office intradiscal injection outpatient rejection, g

  15. Slide 15: ThermoStem Metabolic Program

    METABOLIC PROGRAM THERMOSTEM ® PROGRAM • “Off the shelf” allogeneic cell-based therapy targeted to treat obesity, Type 2 diabetes and metabolic disorders using brown fat stem cells •Brown fat has been shown to regulate metabolic homeostasis in the body • Large library of human brown adipose tissue (

  16. Slide 16: Metabolic Program Highlights

    METABOLIC PROGRAM HIGHLIGHTS First human stem cell derived BAT transfer Creation of first human 3D engineered artificial brown adipose tissue construct (aBAT) Successful delivery delivery of 3D aBAT construct in mouse model Transplantation of aBAT lowered blood glucose levels Transplantation of aBAT

  17. Slide 17: Metabolic Program Clinical Timeline

    METABOLIC PROGRAM CLINICAL TIMELINE Pre-IND Initiate File Meeting Phase DMF 2021 with 2021 with 2022 1/2 FDA FDA Clinical Trial • Expected filing a Drug Master File (“DMF”) with the FDA to facilitate licensing opportunities • Schedule pre-IND (Investigational New Drug) meeting with FDA to discuss fi

  18. Slide 18: Intellectual Property

    INTELLECTUAL PROPERTY • Methods and Compositions to facilitate repair of avascular tissue • Brown Fat Compositions and Methods • Surgical Methods and Compositions to facilitate repair of avascular tissue • Human Brown Adipose Derived Stem Cells and Uses • Therapeutic Delivery Device • Non-naturally

  19. Slide 19: Upcoming Milestones 2021-2022

    Q3 2021 Announce Contracts with Clinical Research Organization (CRO) Announce opening of Cell cGMP Manufacturing Facility Filings of New BRTX-100 Patents File Drug Master File with the FDA Q4 2021 Product Manufacturing Clearance Clinical Sites Established for Disc Trial Generate Clinical Grade Maste

  20. Slide 20: Scientific Advisory Board

    SCIENTIFIC ADVISORY BOARD Clinical Director of WAYNE MARASCO, MD, PhD Chairman of SAB WAYNE OLAN, MD Regenerative Disc / Spine Program Wayne Marasco, M.D., Ph.D. is a principal faculty member of Harvard Stem Cell Dr. Olan is a board-certified Interventional Neuroradiologist and the director of Insti

  21. Slide 21: Company Highlights

    COMPANY HIGHLIGHTS Disruptive Platform Technology in Cellular Therapy Addressing Multi-Billion Dollar Market of Unmet Needs Diverse Pipeline Opportunities Strong Preliminary Data Indicative of Positive Trial Outcomes Multiple Clinical & Regulatory Accomplishments Strong Intellectual Property Protect

  22. Slide 22: BioRestorative Therapies

    EZ ——> bic eclorcie therapies

BioRestorative Therapies — Investor Presentation (June 2021) on 6ix